New CDC Guidance shortens isolation and quarantine period for Covid-19; patients that tested positive should isolate for 5 days and, if asymptomatic after this period, can leave isolation if they can continue to mask for 5 days to minimize the risk of inf
CDC Updates and Shortens Recommended Isolation and Quarantine Period for General Population – Centers for Disease Control and Prevention See also: Quarantine and Isolation – Centers for Disease Control and Prevention Commentaries: Facing criticism, CDC updates Covid-19 isolation recommendations with guidance on testing – CNN CDC posts rationale for shorter isolation, quarantine – Associated Press […]
The post New CDC Guidance shortens isolation and quarantine period for Covid-19; patients that tested positive should isolate for 5 days and, if asymptomatic after this period, can leave isolation if they can continue to mask for 5 days to minimize the risk of infecting others. appeared first on Links Medicus.
Breakthrough infections generate ‘super immunity’ to COVID-19, study suggests.
News Release: Breakthrough infections generate ‘super immunity’ to COVID-19, study suggests – Oregon Health & Science University Original Study: Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection – JAMA
The post Breakthrough infections generate ‘super immunity’ to COVID-19, study suggests. appeared first on Links Medicus.
Covid-19: Runny nose, headache, and fatigue are commonest symptoms of Omicron, early data show.
Covid-19: Runny nose, headache, and fatigue are commonest symptoms of omicron, early data show – The BMJ See also: Omicron and cold-like symptoms rapidly taking over in London – ZOE COVID Study Commentary on Twitter The UK government has been urged to update its list of symptoms for covid-19, after early data showed cold-like […]
The post Covid-19: Runny nose, headache, and fatigue are commonest symptoms of Omicron, early data show. appeared first on Links Medicus.
RCT: Among patients hospitalized with COVID-19 at increased risk for venous thromboembolism, post-discharge thromboprophylaxis with Rivaroxaban for 35 days may improve outcomes.
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial – The Lancet Invited commentary: Anticoagulation in COVID-19 – The Lancet Commentary on Twitter NEW: The role of extended thromboprophylaxis in patients hospitalised with COVID-19 at risk for thrombotic events after discharge – findings from MICHELLE […]
The post RCT: Among patients hospitalized with COVID-19 at increased risk for venous thromboembolism, post-discharge thromboprophylaxis with Rivaroxaban for 35 days may improve outcomes. appeared first on Links Medicus.
RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients – New England Journal of Medicine Related: Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature (several articles on the subject)
The post RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19. appeared first on Links Medicus.
Randomized trial with nearly 30.000 individuals showed Novavax vaccine was safe and had an overall efficacy of 90.4% against symptomatic infections.
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico – New England Journal of Medicine Commentaries: Novavax COVID vaccine shows 90.4% efficacy against infection – CIDRAP Novavax COVID-19 vaccine found to be safe and effective – University of Maryland School of Medicine Related: [Preprint] In RCT with 29,949 participants, the Novavax […]
The post Randomized trial with nearly 30.000 individuals showed Novavax vaccine was safe and had an overall efficacy of 90.4% against symptomatic infections. appeared first on Links Medicus.
WHO issues interim recommendations for heterologous COVID-19 vaccine schedules.
Interim recommendations for heterologous COVID-19 vaccine schedules – World Health Organization Commentary: Coronavirus: WHO gives the nod for mix-and-match vaccine schedules – South China Morning Post
The post WHO issues interim recommendations for heterologous COVID-19 vaccine schedules. appeared first on Links Medicus.
Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.
Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature Related: FDA panel narrowly recommends authorization of first antiviral pill to treat COVID. [Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute […]
The post Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”. appeared first on Links Medicus.
[Not published yet] Initial data from South Africa showed vaccine protection vs. Omicron infection may drop to 30% but does cut severe disease.
Vaccine protection vs. omicron infection may drop to 30% but does cut severe disease – NPR See also: South Africa Omicron study finds drop in vaccine protection, fewer hospitalized – CIDRAP
The post [Not published yet] Initial data from South Africa showed vaccine protection vs. Omicron infection may drop to 30% but does cut severe disease. appeared first on Links Medicus.
Rapidly spreading Omicron is now in 77 countries and WHO warns against assuming its effects are mild.
Rapidly Spreading Omicron is Now in 77 Countries and WHO Warns Against Assuming its Effects are Mild – Health Policy Watch
The post Rapidly spreading Omicron is now in 77 countries and WHO warns against assuming its effects are mild. appeared first on Links Medicus.